{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02706132",
      "OrgStudyIdInfo": {
        "OrgStudyId": "2015-08"
      },
      "Organization": {
        "OrgFullName": "Third Affiliated Hospital, Sun Yat-Sen University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Therapeutic Strategy and the Role of Mesenchymal Stromal Cells for ABO Incompatible Liver Transplantation",
      "OfficialTitle": "MSC for ABO Incompatible Liver Transplantation"
    },
    "StatusModule": {
      "StatusVerifiedDate": "March 2016",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "February 2014"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2016",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 2017",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "March 8, 2016",
      "StudyFirstSubmitQCDate": "March 8, 2016",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "March 11, 2016",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "March 8, 2016",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "March 11, 2016",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Yang Yang",
        "ResponsiblePartyInvestigatorTitle": "Department of Liver Transplantation",
        "ResponsiblePartyInvestigatorAffiliation": "Third Affiliated Hospital, Sun Yat-Sen University"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Third Affiliated Hospital, Sun Yat-Sen University",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to determine whether MSCs are safe and effective in reducing the primary nonfunction (PNF), acute rejection and Ischemic-type Biliary Lesions (ITBLs) morbidity in ABO-incompatible Liver Transplantation.",
      "DetailedDescription": "ABO incompatible liver transplantations is considered to be a rescue option in emergency transplantation.The A、B antibodies to grafts bind to the graft endothelium and activate complement, which attracts and activates neutrophils and platelets and increases the permeability of the endothelium. The neutrophils exude, the platelets aggregate, and the small vessels of the graft get thrombosed, resulting in ischemic damage,leading nonfunction grafts.In addition, if the A、 B antibodies remain high level, it can lead to acute humoral immune rejection. A lot of research confirmed that the ABO incompatible is a risk factor of postoperative short- and long-term survival. And mesenchymal stromal cells (MSCs) are characterized by the properties of immunosuppressive and regenerative properties, which make MSCs great attractive in treating immunological diseases (including transplant rejection) and organ/tissue ischemic injury. So we conduct this clinical study,to confirm the effect of MSCs in ABO incompatible liver transplantation by comparing the incidence of primary nonfunction, acute rejection, biliary complications and survival rates."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Liver Transplantation"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Mesenchymal stromal cells",
          "Liver Transplantation",
          "ABO blood group"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Prevention",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "15",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "The MSCs group",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "The group of patients receive allogeneic MSCs therapies.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Mesenchymal Stem Cells(MSCs)"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Mesenchymal Stem Cells(MSCs)",
            "InterventionDescription": "Six doses of 1*10^6/kg body weight MSCs are given, intravenously.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "The MSCs group"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Efficacy: one year graft survival rate",
            "PrimaryOutcomeTimeFrame": "one year"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "the rate of acute rejection",
            "SecondaryOutcomeTimeFrame": "one year"
          },
          {
            "SecondaryOutcomeMeasure": "the rate of ischemic-type biliary lesions",
            "SecondaryOutcomeTimeFrame": "one year"
          },
          {
            "SecondaryOutcomeMeasure": "safety: rate of (serious) adverse events in the study population",
            "SecondaryOutcomeDescription": "adverse events include: allergic reaction, prothrombotic effects, opportunistic infections and malignancy",
            "SecondaryOutcomeTimeFrame": "one year"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nFirst liver transplantation with a ABO-incompatible graft(B→A，AB→A，A→B，AB→B，A→O，B→O，AB→O).\nAges of 18 or older.\nPatients receive liver transplantation due to benign end stage liver disease.\nPatients or legal agent must be able to give informed consent.\n\nExclusion Criteria:\n\nSecond or combined organ transplant recipient.\nCombined transplantations such as simultaneous liver/kidney transplants\nMalignant disease.\nUncontrol bacterial, fungal, viral or parasitic infection.\nWithdraw or unable to finish the follow-up.\nUnwilling to sign informed consent.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "60 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Yang Yang",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "862085252276",
            "CentralContactEMail": "yysysu@163.com"
          },
          {
            "CentralContactName": "Zhang Yingcai",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "862085252177",
            "CentralContactEMail": "76207884@qq.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Yang Yang",
            "OverallOfficialAffiliation": "Third Affiliated Hospital, Sun Yat-Sen University",
            "OverallOfficialRole": "Study Chair"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "The Third Affiliated Hospital,Sun Yat-sen University",
            "LocationStatus": "Recruiting",
            "LocationCity": "Guangzhou",
            "LocationState": "Guangdong",
            "LocationZip": "510630",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Zhang Yingcai",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "862085252177",
                  "LocationContactEMail": "76207884@qq.com"
                }
              ]
            }
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M10262",
            "InterventionBrowseLeafName": "Liver Extracts",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Hemat",
            "InterventionBrowseBranchName": "Hematinics"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}